Here are the S-3 shelf registrations from Erasca, Inc. (ERAS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow ERAS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERAS filings page.
Erasca, Inc., a Delaware-based clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway–driven cancers, has filed an automatic shelf registration as a well-known seasoned issuer. The shelf allows Erasca to offer, from time to time after effectiveness, various securities, including common stock, preferred stock, debt securities, warrants and units, with specific terms and amounts to be set in future prospectus supplements. Any securities may be sold through underwriters, dealers, agents, directly to investors, or a combination of these methods.
As of March 31, 2026, Erasca’s authorized capital stock consists of 800,000,000 shares of common stock and 80,000,000 shares of preferred stock. Its common stock trades on the Nasdaq Global Select Market under the symbol ERAS, with a last reported price of $18.53 per share on July 10, 2026. The company’s pipeline includes two clinical-stage programs, ERAS-0015 (a pan-RAS molecular glue) and ERAS-4001 (a pan-KRAS inhibitor), plus ERAS-12 (an EGFR D2/D3 biparatopic antibody) in discovery. The filing also describes existing registration rights that permit certain holders to demand registrations for offerings of at least $20.0 million on Form S-1 and $5.0 million on Form S-3, with those rights expiring in August 2026, as well as anti-takeover and forum-selection provisions.